OBEROIRLTY’s FY26 topline growth hinges on launch execution (50% probability of partial slippage), while FY27’s “big year” thesis requires flawless RERA/commencement timelines; margins are structurally supported by premium pricing but vulnerable to absorption risks in Goregaon/Borivali, and FCF inflection is deferred to FY27 pending land monetization.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) 50% of Q4 FY26 launches execute (Goregaon, Borivali, but NCR slips); (2) Premium demand holds (Rs. 50,000+/sq. ft. sales at 70% of inventory); (3) Sky City leasing hits 80% by FY26-end.
Outcome: Revenue growth 15–20% YoY in FY27 (spillover effect), margins stable (±50 bps) on pricing power; FCF breakeven by H2 FY27 as land spends monetize. Thane’s mixed-use projects gain traction, adding Rs. 1,500 crore to pipeline.
ADANIGREEN’s topline growth hinges on grid evacuation timing and merchant price recovery, while bottomline resilience depends on storage arbitrage execution and commodity cost containment; margins remain structurally high (90%+) but face cyclical pressure from wind volatility and merchant pricing.
1–2 minutes
3-Scenario Framework
📊 Base Case (60% Probability)
Grid augmentation completes by March 2026 (2–3 GW), and wind speeds normalize in H1 FY27. Merchant realizations recover to ₹2.50–3.00/unit (solar) on peak demand. Battery storage (3.5 GWh) operationalizes as planned, enabling 10–15% revenue uplift from arbitrage. EBITDA margin sustains at 90%+, with ₹16,000 crore power supply EBITDA achieved by FY26 end. Debt/EBITDA improves to 5x by FY27.
Dr.Reddy’s topline growth hinges on Semaglutide/Abatacept execution and EM resilience, while margins face structural pressure from Lenalidomide exit, FX, and biosimilar delays; base case implies 6–8% revenue growth with 24–26% EBITDA, but bear-case risks skew asymmetric.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Semaglutide launches in Canada (May 2026, $50/unit) and India (March 2026, $30/unit), contributing $150–200M revenue. Abatacept EU approval (July 2027) and US Rituximab re-inspection (H1CY27) proceed as guided. EM grows 20% YoY; India sustains 15%+ organic growth. EBITDA margins recover to 24–26% on cost controls. Implication: 6–8% revenue growth; 10–12% EPS growth.
Axis Bank’s base case sees NIM stabilizing near 3.6–3.7% with ROE at 14–15%, while bear case risks compression to 3.4–3.5% and ROE 12–13%. Bull case offers upside with NIM above 3.8% and ROE 16%+, hinging on deposit growth and digital monetization.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Triggers: Deposit growth converges in 15–18 months, retail disbursements sustain +20% YoY, no further rate cuts. Outcome: NIM stabilizes at 3.6–3.7% (Q4 dip offset by 2027 rebalancing), credit costs 60–70 bps, ROE 14–15%. CET-1 remains >14% (AT1 issuance likely). Action: Model 58–60% retail mix by FY28, watch Neo platform monetization.
TATACOMM’s topline: 8–12% CAGR feasible if digital (15% YoY) offsets core cyclicality (3–5% YoY); Bottomline: EBITDA margin expansion to 22–25% hinges on AI/SaaS execution and cost discipline; Margins: Structural upside in cloud/security (18.9% YoY) and CIS (post-contract exits), but media/MOVE drag persists.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) Commotion pilots convert to revenue (10% digital growth by FY27); (2) Core connectivity stabilizes (3–4% YoY growth).
Outcome: Digital breakeven by FY27; EBITDA margins expand to 22% by FY28. Revenue CAGR of 8–10%, driven by cloud/security (18.9% YoY) and next-gen connectivity (17% YoY). FCF: INR 1,200–1,500 Cr annualized post-FY26.
PERSISTENT sustains 15–20% growth with BFSI, healthcare, and AI as drivers. Margins stay range-bound at 14–16% amid structural pressures, while AI monetization and disciplined cash flow management shape profitability.
Revenue grows 15–17% YoY, driven by BFSI/Healthcare modernization and hi-tech product development. Top 100 clients expand at 18–20% YoY.
EBIT margin stabilizes at 14–15%, with labour code impact offset by AI productivity gains. Operating cash flow recovers to 95–100% of PAT as DSO normalizes to 55 days.
EPS rises to ₹30–32, supporting dividend hikes (₹24–26/share) and selective M&A for AI/data capabilities.
DLF’s topline resilient (FY26 guidance intact; FY27 pipeline robust), margins protected by pricing power and cost discipline, but execution risks (GRAP, RERA, contractors) cap near-term upside; FCF growth hinges on RERA unlock and land monetization timing.
TATACAP’s topline growth (18–20% AUM) and margin stability (NIM 6.6%) are credible, but bottomline upside (PAT growth) hinges on credit cost trajectory (1.0–1.2%) and Motor Finance execution, with structural tech efficiency offsetting cyclical macro risks.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: Unsecured retail slippages stabilize; Motor Finance AUM grows 5–7% YoY; housing margins hold at 2.4% ROA.
Outcome: Credit costs trend to 1.0–1.1%; consolidated ROA at 2.0–2.2%. AUM growth at 18–20%. NIM expansion of 5–10bps on funding cost tailwinds.
ICICIBANK’s outlook splits into Base Case with NIM steady at 3.0–4.3% and ROE 15–21%; Bear Case with margin compression to 2.8–4.0% and ROE 13–14%; Bull Case with NIM expansion above 3.1–4.4% and ROE 17–22%.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) PSL portfolio conformity achieved by H1-2027, limiting provisions to ₹12.83B; (2) Retail deposit repricing offsets 50% of repo cut impacts. Outcome: PBT grows 3–5% YoY (adjusted for provisions), with NIM stable at 4.20–4.30%. Loan growth sustains at 11–12% YoY, led by business banking. RoE holds at 15–16%. Signal: Credit card/personal loan growth recovers to 8–10% YoY by H2-2027.
NETWEB’s topline likely to sustain 30–40% CAGR on AI/HPC tailwinds, but lumpiness in strategic orders and ASIC disruption risks could compress margins (9–12% PAT range) and cash flow visibility; modeling should prioritize annualized trends over quarterly volatility.
1–2 minutes
3-Scenario Framework
📊 Base Case (50% Probability)
Key Variables: (1) AI mission executes as planned (₹17B strategic orders over 3 years); (2) ASICs remain niche (<10% of AI market).
Outcome: 30–40% organic CAGR sustained; AI systems contribute 50–60% of revenue. Margins stabilize at 9–10% PAT (13–14% ex-strategic). PLI approvals add 100–150 bps to EBITDA. Implication: ₹20B+ topline by FY28; 15–20% EPS CAGR.
